Keywords: 9vHPV; 9-valent human papillomavirus; AE; adverse event; Cl; confidence interval; CIN; cervical intraepithelial neoplasia; GMT; geometric mean titer; HPV; human papillomavirus; HPV-9 cLIA; 9-valent competitive Luminex immunoassay; mMU; milli-Merck units;